From public research to business innovation!

Predictive test of the response to anti-TNFα treatment

Domain Health and wellbeing

Technology Metaomic


  • Microbiota biomarker to predict positive response to anti-TNFα treatment
  • Ankylosing spondylitis, Crohn's disease, ulcerative colitis anti-TNF therapy
  • Other inflammatory diseases such as psoriasis, rheumatoid arthritis, psoriatic arthritis,, for which anti-TNF therapy is prescribed.


Although effective in blocking the mechanisms of chronic rheumatic inflammation, anti-TNF are expensive biotherapies that may present infectious risks. They are therefore prescribed after observation and in 2nd line after NSAIDs and failure of methotrexate.

This technology is a test which detects a level of expression of burkholderia bacteria  in the microbiota of patients with Ankylosing spondylitis, Ulcerative colitis and Crohn disease for earlier and more efficient treatment with anti-TNF.


  • Adapted anti -TNF therapy
  • Predictive efficacy
  • Earlier prescription
  • Adverse effets preservation for non-responding patients
  • Customized dosage
  • Reduced cost of disease management (for
    non-responding patients, and in general with reduction on NSAID consumption)



Head of the Rheumatology department

Bordeaux University Hospital Center

Medical coordinator of ACRONIM


Jean-Luc Chagnaud


We also recommend...